| Objective: To observe the clinical efficacy of the modified Anshen Dingzhi Pill combined with escitalopram treatment of depression with Xindan Qixu syndrome and the state of fright and palpitation,in order to provide certain clinical basis for the treatment of depression with integrated Traditional Chinese and Western medicine.Methods: Patients with depression with the syndrome of Xindan Qixu and the state of fright and palpitation were the subjects of the study.A total of 64 patients with depression who met the inclusion criteria were selected in Shandong University of Traditional Chinese Medicine(TCM)hospital from December 2020 to October 2021.The patients who met the inclusion criteria were divided into treatment group and control group according to the randomization method of numerical random table.The control group was given escitalopram,and the treatment group was given Chinese medicine modified Anshen Dingzhi Pill on the basis of the control group.The treatment period of both groups was 8 weeks.The Hamilton Depression scale(HAMD-17),the TCM Xindan Qixu syndrome scale and the TCM fright and palpitation scale were used to evaluate the therapeutic effect of the two groups before and after treatment.To observe the clinical efficacy of the modified Anshen Dingzhi Pill combined with escitalopram in the treatment of depression with Xindan Qixu syndrome and the state of fright and palpitation,and to evaluate scientifically and standardized.Results:1.There were no statistical significance in the basic data of patients in the two groups,such as gender,age and duration of disease,and the data were comparable(P>0.05).2.Score of HAMD-17: There was no statistical significance in HAMD-17 score before treatment between the two groups(P>0.05).After 8 weeks of treatment,the HAMD-17 scores of both groups were significantly lower than those before treatment(P<0.01),and the efficacy in the treatment group was better than that in the control group(P<0.05).3.Score of TCM Xindan Qixu syndrome scale: There was no statistical significance in score of TCM syndrome integral scale between the two groups before treatment(P>0.05).After 8 weeks of treatment,the scores of TCM syndrome scale in both groups were significantly lower than those before treatment(P<0.01),and the efficacy in the treatment group was better than that in the control group(P<0.05).4.Score of TCM fright and palpitation scale: There was no significant difference in score of TCM fright and palpitation scale between the two groups before treatment(P>0.05).After 8 weeks of treatment,the scores of TCM fright and palpitation scale in both groups decreased significantly(P<0.01),and the efficacy in the treatment group was better than that in the control group(P<0.05).5.High-frequency items of Xindan Qixu syndrome: Some high-frequency items of Xindan Qixu syndrome scale before treatment were compared between the two groups,and there was no significant difference between the two groups(P>0.05).After treatment,the efficacy of the treatment group was better than the control group on“mental depression”“loss of appetite”“easily frightened”and“insomnia”(P<0.05).6.High-frequency items of the state of fright and palpitation: Some high-frequency items of fright and palpitation scale before treatment were compared between the two groups,and there was no significant difference between the two groups(P>0.05).After treatment,the efficacy of the treatment group was better than the control group on“often fidgeting”“suspicious and worried about gains and losses”“contact with some adverse stimuli that is afraid”and“often cry because of the feeling of powerlessness”(P<0.05).7.Clinical efficacy: The total effective rate of HAMD evaluation was86.67% in the treatment group and 80.00% in the control group.The total effective rate of Xindan Qixu syndrome was 90.00% in the treatment group and73.33% in the control group.The total effective rate of the state of fright and palpitation was 93.33% in the treatment group and 80.00% in the control group.There were statistically significant differences in clinical efficacy between the two groups(P<0.05),and the efficacy of the treatment group was better than the control group.8.Safety index test: No serious adverse reactions occurred in patients in both groups.Conclusions:1.Modified Anshen Dingzhi Pill combined with escitalopram can significantly improve the condition of patients with depression with the syndrome of Xindan Qixu and the state of fright and palpitation.The improvement of HAMD score,TCM syndrome score and TCM fright and palpitation score is better than that of escitalopram alone,and there is no obvious adverse reaction,which has certain clinical significance.2.In terms of the scoring of each item of TCM syndrome and TCM psychology,the efficacy of modified Anshen Dingzhi Pill combined with escitalopram was better than escitalopram on“mental depression”“loss of appetite”“easy to panic”“insomnia”“constant restlessness”“paranoia and worry”“worry about gain and loss”“feel afraid when exposed to some bad stimulus”“often cry because of the feeling of powerlessness”(P<0.05). |
PDF Full Text Request